Hansa Medical to present IdeS at the 2014 World Transplant Congress in San Francisco, July 27

Hansa Medical will present the drug candidate IdeS’s potential as a novel
treatment for desensitization prior to kidney transplantation, at the poster
session on July 27 at the 2014 World Transplant Congress in San Francisco, USA.
The World Transplant Congress gathers international experts on transplantation,
attracts prominent keynote speakers as well as pharmaceutical and biotechnology
companies committed to the improvement of treatment of transplantation patients.

For more information about the World Transplant Congress, please visit:
www.wtc2014.org

The poster presentation will emphasize IdeS’ antibody deactivating effect and
safety, demonstrated in a recently concluded Phase I study in healthy volunteers
as well as in sera from sensitized patients pre-kidney transplantation.

More on IdeS
Hansa Medicals’ drug candidate IdeS is developed as a fast, safe and expedient
method to deactivate IgG-antibodies in sensitized patients prior to kidney
transplantation. For sensitized patients, IgG-antibodies pose the primary
obstacle for a transplant, forcing patients into years of treatment in dialysis.
A successful Phase I-study was finalized in January 2014 and a Phase II study is
planned for 2014 in sensitized patients awaiting kidney transplantation.
For further information, please contact:
Hansa Medical AB
Emanuel Björne, CEO Hansa Medical AB (publ)
Mobile: 46 707 17 54 77
E-mail: emanuel.bjorne@hansamedical.com
www.hansamedical.com
Hansa Medical pursues clinical development and commercialization of innovative
pharmaceuticals and diagnostic methods for the benefit of patients with serious
and rare inflammatory diseases. The portfolio includes a marketed diagnostic
product, a drug candidate in clinical development, and a preclinical research
project. Major shareholders are Bo Håkansson via Farstorps Gård AB, and Nexttobe
AB. Hansa Medical is listed on NASDAQ OMX First North (HMED) and Remium Nordic
AB is the company’s Certified Adviser.